TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

Tolaney, Sara M; Arteaga, Carlos; Cortés Castan, Javier; Sohn, Joohyuk; Rugo, Hope; Bardia, Aditya

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Tolaney, Sara M
dc.contributor.author	Arteaga, Carlos
dc.contributor.author	Cortés Castan, Javier
dc.contributor.author	Sohn, Joohyuk
dc.contributor.author	Rugo, Hope
dc.contributor.author	Bardia, Aditya
dc.date.accessioned	2021-10-22T09:06:05Z
dc.date.available	2021-10-22T09:06:05Z
dc.date.issued	2020-04
dc.identifier.citation	Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, et al. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Futur Oncol. 2020 Apr;16(12):705–715.
dc.identifier.issn	1744-8301
dc.identifier.uri	https://hdl.handle.net/11351/6446
dc.description	HER2-negative; Metastatic breast cancer; Sacituzumab govitecan
dc.description.abstract	Patients with HR+/HER2- metastatic breast cancer (MBC) whose cancers have progressed despite conventional therapies represent an unmet clinical need. Trop-2, a transmembrane calcium signal transducer, is highly expressed in MBC and plays a role in tumor growth and progression. Sacituzumab govitecan (SG) is a novel antibody–drug conjugate comprising an Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan, via a unique hydrolyzable linker. SG has demonstrated promising activity in a Phase I/II IMMU-132-01 basket study in heavily pretreated solid tumors, including HR+/HER2- MBC. We describe the registrational Phase III TROPiCS-02 study (NCT03901339), evaluating SG versus treatment of physician’s choice in HR+/HER2- MBC.
dc.language.iso	eng
dc.publisher	Future Medicine
dc.relation.ispartofseries	Future Oncology;16(12)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Mama - Càncer - Quimioteràpia
dc.subject	Metàstasi
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	/drug therapy
dc.subject.mesh	Neoplasm Metastasis
dc.title	TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.2217/fon-2020-0163
dc.subject.decs	neoplasias de la mama
dc.subject.decs	/farmacoterapia
dc.subject.decs	metástasis neoplásica
dc.relation.publishversion	https://doi.org/10.2217/fon-2020-0163
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Rugo HS] Department of Medicine (Hematology/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA. [Bardia A] Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. [Tolaney SM] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. [Arteaga C] Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. [Cortes J] Medical Oncology Department, IOB Institute of Oncology, Quirosalud Group, Madrid & Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Sohn J] Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
dc.identifier.pmid	32223649
dc.identifier.wos	000532009800002
dc.rights.accessrights	info:eu-repo/semantics/openAccess